PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis

Oncogene

Volumn 27, Issue 14, 2008, Pages 2004-2014

  Graf Finckenstein, F ^a   Shahbazian, V ^a   Davicioni, E ^b   Ren, Y X ^a   Anderson, M J ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

MyoD; Pangene; PAX FKHR; Rhabdomyosarcoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; MYOD PROTEIN; MYOGENIN; MYOSIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL LINEAGE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MUSCLE DEVELOPMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; CELL LINE; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUSCLE DEVELOPMENT; MYOD PROTEIN; MYOGENIN; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHORYLATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; RHABDOMYOSARCOMA, ALVEOLAR;

EID: 41149114723     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210835     Document Type: Article

References (27)

1. Anderson J, Ramsay A, Gould S, Pritchard-Jones K. (2001a). PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159: 1089-1096.
2. Anderson MJ, Shelton GD, Cavenee WK, Arden KC. (2001b). Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA 98: 1589-1594.
3. Barr FG. (2001). Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20: 5736-5746.
4. Bernasconi M, Remppis A, Fredericks WJ, Rauscher III FJ, Schafer BW. (1996). Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93: 13164-13169.
5. Chalepakis G, Fritsch R, Fickenscher H, Deutsch U, Goulding M, Gruss P. (1991). The molecular basis of the undulated/Pax-1 mutation. Cell 66: 873-884.
6. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. (2006). Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66: 6936-6946.
7. Davis RJ, Barr FG. (1997). Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 94: 8047-8051.
8. Davis RL, Weintraub H, Lassar AB. (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51: 987-1000.
9. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. (1995). Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270: 11719-11722.
10. Epstein JA, Song B, Lakkis M, Wang C. (1998). Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 18: 4118-4130.
11. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG et al. (1995). The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15: 1522-1535.
12. Goldhamer DJ, Brunk BP, Faerman A, King A, Shani M, Emerson Jr CP. (1995). Embryonic activation of the myoD gene is regulated by a highly conserved distal control element. Development 121: 637-649.
13. Goldhamer DJ, Faerman A, Shani M, Emerson Jr CP. (1992). Regulatory elements that control the lineage-specific expression of myoD. Science 256: 538-542.
14. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. (2004). Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18: 2614-2626.
15. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC et al. (1999). cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96: 13264-13269.
16. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. (1999). The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19: 594-601.
17. Lang D, Lu MM, Huang L, Engleka KA, Zhang M, Chu EY et al. (2005). Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433: 884-887.
18. Li L, Zhou J, James G, Heller-Harrison R, Czech MP, Olson EN. (1992). FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains. Cell 71: 1181-1194.
19. Liu LN, Dias P, Houghton PJ. (1998). Mutation of Thr115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells. Cell Growth Differ 9: 699-711.
20. Lu J, McKinsey TA, Zhang CL, Olson EN. (2000). Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 6: 233-244.
21. Novitch BG, Mulligan GJ, Jacks T, Lassar AB. (1996). Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J Cell Biol 135: 441-456.
22. Novitch BG, Spicer DB, Kim PS, Cheung WL, Lassar AB. (1999). pRb is required for MEF2-dependent gene expression as well as cell-cycle arrest during skeletal muscle differentiation. Curr Biol 9: 449-459.
23. Puri PL, Sartorelli V. (2000). Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol 185: 155-173.
24. Robson EJ, He SJ, Eccles MR. (2006). A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6: 52-62.
25. Schmidt D, Reimann O, Treuner J, Harms D. (1986). Cellular differentiation and prognosis in embryonal rhabdomyosarcoma. A report from the Cooperative Soft Tissue Sarcoma Study 1981 (CWS 81). Virchows Arch A Pathol Anat Histopathol 409: 183-194.
26. Tapscott SJ, Lassar AB, Weintraub H. (1992). A novel myoblast enhancer element mediates MyoD transcription. Mol Cell Biol 12: 4994-5003.
27. Zhang L, Wang C. (2007). Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene 26: 1595-1605.